DaVita Inc. (NYSE:DVA) Shares Bought by GHP Investment Advisors Inc.

GHP Investment Advisors Inc. increased its holdings in DaVita Inc. (NYSE:DVA) by 0.9% during the 3rd quarter, HoldingsChannel reports. The fund owned 45,725 shares of the company’s stock after acquiring an additional 419 shares during the quarter. GHP Investment Advisors Inc.’s holdings in DaVita were worth $7,496,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. SG Americas Securities LLC boosted its stake in shares of DaVita by 196.9% during the 1st quarter. SG Americas Securities LLC now owns 29,733 shares of the company’s stock valued at $4,105,000 after buying an additional 19,719 shares during the last quarter. Bessemer Group Inc. increased its position in shares of DaVita by 2,335.6% in the 1st quarter. Bessemer Group Inc. now owns 10,741 shares of the company’s stock worth $1,483,000 after purchasing an additional 10,300 shares during the last quarter. Forsta AP Fonden raised its stake in shares of DaVita by 50.3% in the 1st quarter. Forsta AP Fonden now owns 23,600 shares of the company’s stock valued at $3,258,000 after purchasing an additional 7,900 shares in the last quarter. Fox Hill Wealth Management lifted its position in shares of DaVita by 138.4% during the first quarter. Fox Hill Wealth Management now owns 15,734 shares of the company’s stock worth $2,172,000 after purchasing an additional 9,135 shares during the last quarter. Finally, Sei Investments Co. grew its stake in DaVita by 21.3% in the first quarter. Sei Investments Co. now owns 41,952 shares of the company’s stock worth $5,790,000 after purchasing an additional 7,371 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

Shares of DVA stock traded down $4.39 during trading hours on Friday, reaching $156.99. The stock had a trading volume of 854,416 shares, compared to its average volume of 802,997. DaVita Inc. has a twelve month low of $75.47 and a twelve month high of $168.50. The company has a debt-to-equity ratio of 9.94, a current ratio of 1.16 and a quick ratio of 1.12. The firm has a market capitalization of $13.77 billion, a PE ratio of 17.84, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87. The firm has a 50-day simple moving average of $158.09 and a 200-day simple moving average of $145.50.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.47 by $0.12. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The business had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.15 billion. During the same period in the previous year, the business earned $2.08 earnings per share. The company’s revenue was up 6.2% on a year-over-year basis. As a group, equities analysts forecast that DaVita Inc. will post 9.99 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on DVA shares. Truist Financial increased their target price on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. TD Cowen lifted their price objective on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. UBS Group increased their target price on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Finally, Bank of America lifted their price target on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $159.00.

Insider Transactions at DaVita

In related news, CFO Joel Ackerman sold 64,029 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the completion of the transaction, the chief financial officer now owns 111,481 shares of the company’s stock, valued at $17,286,243.86. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Javier Rodriguez sold 50,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the sale, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Joel Ackerman sold 64,029 shares of DaVita stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total value of $9,928,336.74. Following the completion of the transaction, the chief financial officer now owns 111,481 shares in the company, valued at $17,286,243.86. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 173,482 shares of company stock valued at $27,387,069. Corporate insiders own 2.00% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.